menu
    • menu

    Company profile for enGene

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Willow Birch Pharma delivers trusted, high-quality APIs nationwide with unmatched service, compliance, and competitive value.

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    enGene Inc. is a biotechnology company developing a proprietary non-viral gene therapy platform for localized delivery of nucleic acid payloads to mucosal tissues. The dually derived chitosan (DDX) platform has a high-degree of payload flexibility including DNA and various forms of RNA (siRNA, shRNA, lncRNA etc.) with broad tissue and disease applications. In addition to developing EG-70 for BCG-unresponsive NMIBC, enGene enGe...
    enGene Inc. is a biotechnology company developing a proprietary non-viral gene therapy platform for localized delivery of nucleic acid payloads to mucosal tissues. The dually derived chitosan (DDX) platform has a high-degree of payload flexibility including DNA and various forms of RNA (siRNA, shRNA, lncRNA etc.) with broad tissue and disease applications. In addition to developing EG-70 for BCG-unresponsive NMIBC, enGene enGene is developing unique genetic medicines for respiratory indications. The company is also evolving its technology to enable applications in several mucosal tissues.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    enGeneCanada Flag
    Country
    Country
    Canada
    Address
    Address
    7171 Rue Frederick Banting Montreal, QCH4S 1Z9
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.engene.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/engene/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Engene To Present At Piper Sandler Healthcare Conference
    Engene To Present At Piper Sandler Healthcare Conference

    25 Nov 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251125229644/en/enGene-to-Present-at-the-Piper-Sandler-37th-Annual-Healthcare-Conference

    BUSINESSWIRE
    25 Nov 2025
    Share Share
    Engene Prices $130M Public Offering Of Common Shares & Warrant
    Engene Prices $130M Public Offering Of Common Shares & Warrant

    13 Nov 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251112537822/en/enGene-Announces-Pricing-of-%24130-Million-Public-Offering-of-Common-Shares-and-Pre-Funded-Warrants

    BUSINESSWIRE
    13 Nov 2025
    Share Share
    enGene Plans Public Offering Of Common Shares
    enGene Plans Public Offering Of Common Shares

    12 Nov 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251112104478/en/enGene-Announces-Proposed-Public-Offering-of-Common-Shares

    BUSINESSWIRE
    12 Nov 2025
    Share Share
    Detalimogene Shows 62% Complete Response Rate At 6 Months
    Detalimogene Shows 62% Complete Response Rate At 6 Months

    11 Nov 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251111033184/en/Detalimogene-Demonstrates-Improved-Complete-Response-Rate-of-62-at-6-Months

    BUSINESSWIRE
    11 Nov 2025
    Share Share
    enGene To Host Conference Call On Pivotal Cohort of LEGEND Trial
    enGene To Host Conference Call On Pivotal Cohort of LEGEND Trial

    10 Nov 2025

    // BUSINESS WIRE

    https://www.businesswire.com/news/home/20251110861491/en/enGene-to-Host-Conference-Call-to-Provide-Update-on-Pivotal-Cohort-of-LEGEND-Trial

    BUSINESS WIRE
    10 Nov 2025
    Share Share
    Engene To Join Investor Conferences
    Engene To Join Investor Conferences

    06 Nov 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251106754185/en/enGene-to-Participate-in-Upcoming-Investor-Conferences

    BUSINESSWIRE
    06 Nov 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search